Table 1.
Clinical characteristics according to the TMT measurement.
| No. (%) | TMT on CT (mm) | P value | ||
|---|---|---|---|---|
| > 6.24 mm | ≤ 6.24 mm | |||
| No. (%) | 106 (100%) | 53 (50%) | 53 (50%) | NA |
| Mean age (years) | 68.8 ± 2.8 | 64.1 ± 0.8 | 0.038* | |
| Sex | ||||
| Men | 84 (79.2%) | 38 (71.7%) | 46 (86.8%) | 0.056 |
| Women | 22 (20.8%) | 15 (28.3%) | 7 (13.2%) | |
| Smoking status | ||||
| Never smoked | 56 (52.8%) | 31 (58.5%) | 25 (47.2%) | 0.195 |
| Former smoker | 26 (24.5%) | 9 (17.0%) | 17 (32.1%) | |
| Current smoker | 24 (22.6%) | 13 (24.5%) | 11 (20.8%) | |
| Treatment modality | ||||
| Initial surgery | 13 (12.3%) | 7 (13.2%) | 6 (11.3%) | 0.739 |
| Surgery after neoadjuvant chemoradiation | 37 (34.9%) | 20 (37.7 5) | 17 (32.1%) | |
| Adjuvant radiation or chemoradiation | 37 (34.9%) | 20 (37.7 5) | 17 (32.1%) | |
| Human papillomavirus | ||||
| Negative | 79 (74.5%) | 41 (77.4%) | 38 (71.7%) | 0.505 |
| Positive | 27 (25.5%) | 12 (22.6%) | 15 (28.3%) | |
| Tumor site | ||||
| Sinonasal cavity | 8 (7.5%) | 5 (9.4%) | 3 (5.7%) | 0.944 |
| Oral cavity | 17 (16.0%) | 9 (17.0%) | 8 (15.1%) | |
| Nasopharynx | 14 (13.2%) | 6 (11.3%) | 8 (15.1%) | |
| Oropharynx | 33 (31.1%) | 17 (32.1%) | 16 (30.2%) | |
| Hypopharynx | 12 (11.3%) | 5 (9.4%) | 7 (13.2%) | |
| Larynx | 22 (20.8%) | 11 (20.8%) | 11 (20.8%) | |
| cT category | ||||
| T1 | 16 (15.1%) | 5 (9.4%) | 11 (20.8%) | 0.103 |
| T2 | 31 (29.2%) | 13 (24.5%) | 18 (34.0%) | |
| T3 | 27 (25.5%) | 18 (34.0%) | 9 (17.0%) | |
| T4 | 32 (30.2%) | 17 (32.1%) | 15 (28.3%) | |
| cN category | ||||
| N0 | 43 (40.6%) | 22 (41.5%) | 21 (39.6%) | 0.749 |
| N1 | 25 (23.6%) | 12 (22.6%) | 13 (24.5%) | |
| N2 | 27 (25.5%) | 12 (22.6%) | 15 (28.3%) | |
| N3 | 11 (10.4%) | 7 (13.2%) | 4 (7.5%) | |
| cM category | ||||
| M0 | 53 (50.0%) | 48 (48.5%) | 5 (71.4%) | 0.243 |
| M1 | 53 (50.0%) | 51 (51.5%) | 2 (28.6%) | |
| Overall stage | ||||
| I | 18 (17.0%) | 6 (11.3%) | 12 (22.6%) | 0.383 |
| II | 20 (18.9%) | 10 (18.9%) | 10 (18.9%) | |
| III | 34 (32.1%) | 17 (32.1%) | 17 (32.1%) | |
| IV | 34 (32.1%) | 20 (37.7%) | 14 (26.4%) | |
| Preoperative serum albumin (g/dL) | 4.19 ± 0.47 | 4.04 ± 0.56 | 0.134 | |
The patients were dichotomized according to the median TMT value.
TMT temporalis muscle thickness, cT clinical tumor, cN clinical node, cM clinical metastasis, NA not applicable.
*P value less than 0.05 indicates statistical significance.